Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OK5R
|
|||
| Former ID |
DIB008946
|
|||
| Drug Name |
OP-R003
|
|||
| Synonyms |
VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK
Click to Show/Hide
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Company |
Vaccinex Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034097) | |||
| REF 2 | A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.